Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-Dose, Randomized, Open-Label, Two-Sequence, Two-Period, Double-Crossover, Bioequivalence Study of Liposomal Amphotericin B for Injection in Healthy Chinese Subjects

NCT06983665 is registered in ClinicalTrials.gov with Sichuan Huiyu Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT06983665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06983665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-Dose, Randomized, Open-Label, Two-Sequence, Two-Period, Double-Crossover, Bioequivalence Study of Liposomal Amphotericin B for Injection in Healthy Chinese Subjects
Lead sponsor
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase
Not applicable
Overall status
Completed
Start date
May 25, 2025
Completion date
March 9, 2026
Enrollment
58 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

invasive fungal infections, neutropenic fever, visceral leishmaniasis